TerminatedPHASE1, PHASE2NCT02605083
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Studying Malignant germ cell tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Effector Therapeutics
- Principal Investigator
- Jeremy Barton, MDEffector Therapeutics
- Intervention
- eFT508(drug)
- Enrollment
- 66 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2019
Study locations (4)
- SCRI at HealthONE, Denver, Colorado, United States
- Florida Cancer Specialists, Sarasota, Florida, United States
- Tennessee Oncology, PLLC, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02605083 on ClinicalTrials.govOther trials for Malignant germ cell tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04804007Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCTNabil Adra
- RECRUITINGPHASE1NCT04038619Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT02830724Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersNational Cancer Institute (NCI)